Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445392 | 1.00 | CFTR (0.80) | CFTR | |
| SCHEMBL16446349 | 0.91 | CFTR (0.83) | CFTR | |
| SCHEMBL16445424 | 0.89 | CFTR (1.00) | CFTR | |
| SCHEMBL16445365 | 0.86 | CFTR (1.00) | CFTR | |
| SCHEMBL16450556 | 0.84 | CFTR (0.80) | CFTR | |
| SCHEMBL16445539 | 0.83 | CFTR (0.78) | CFTR | |
| SCHEMBL17467829 | 0.83 | CFTR (0.79) | CFTR | |
| SCHEMBL17467828 | 0.83 | CFTR (0.76) | CFTR | |
| SCHEMBL16445464 | 0.82 | CFTR (0.75) | CFTR | |
| SCHEMBL16445844 | 0.82 | CFTR (0.75) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | claimed |
| CN-114671864-A | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-109311864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-113912617-A | Substituted tricycles and methods of use | 艾伯维公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-108349930-B | Substituted tricycles and methods of use | 艾伯维公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-107405337-B | Substituted chromans and methods of use | 艾伯维公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-108513574-B | N-sulfonylated pyrazolo [3, 4-b ] pyridine-6-carboxamides and methods of use | 艾伯维公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-111954664-A | Cystic fibrosis transmembrane conductance regulator and methods of use | 艾伯维海外有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3486246-A1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | Galapagos N.V. (BE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3030568-B1 | THIENO[2,3-C]PYRANS AS CFTR MODULATORS | GALAPAGOS NV (BE) | 2018-09-19 | — | — | EP | disclosed |
| US-9895347-B2 | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | GALAPAGOS NV (BE) | 2018-02-20 | — | — | US | disclosed |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | ABBVIE S.Á.R.L. (LU) | 2018-02-08 | — | — | US | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221334-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CFTR 1/4885 |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | CFTR 1/4885 |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | CFTR, F12, CHRM2 | CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.